Press Release

(2022-05-17) Aimedbio develops antibodies with novel targets based on ‘patient big data’
2023.02.28
- Nam-gu Her, Aimedbio’s Head of R&D, gives a speech on ‘Introduction to Aimedbio’s patient-centric AI novel drug therapeutics development and precision medicine’ at BIOKOREA 2022
- AimedBio uses patient big data and patient-derived samples to develop novel antibody-based therapeutics with high speed and accuracy

Link to full news: http://www.biospectator.com/view/news_view.php?varAtcId=1628

IR/PR